In primary CML stem-enriched and progenitor populations, 5 µM imatinib for 4 hours suppressed phosphotyrosine and BCR-ABL substrate phosphorylation under serum/cytokine-free conditions. Residual phosphorylation remained. Phospho-CRKL flow cytometry did not reproduce the immunoblot response in primary cells, emphasizing the importance of assay choice. These acute signaling endpoints do not establish elimination of CML stem cells. [2]
Imatinib binding to the inactive ABL kinase domain
Biochemical assay · Isolated murine c-Abl kinase domain (residues 229–515), unphosphorylated; X-ray complex with synthesized STI-571 [1]
The full imatinib molecule occupies the ATP-binding cleft and stabilizes an inactive activation-loop conformation. PD173955 provides a structural comparator with a different activation-loop conformation.
Literature-Reported Treatment Conditions
- Method
- In vitro co-complex formation for X-ray crystallography.
- Vehicle
- DMSO used for inhibitor stock.
- Reported limits
- Salt/counterion and product lot are not specified. This is a structural experiment, not a cellular treatment-dose experiment.
Methods and source locations
Compound reported in the paper: Imatinib; Compound label in the paper: STI-571
Evidence for the imatinib molecule in the reported system; no validation of Adooq A10259 lots, formulation equivalence or free-base/salt dose conversion.
Table 1; Figures 1a and 3; pp. 4237–4240, structural Methods and Results
Diffraction resolution of ABL:STI-571 structure: X-ray crystallography; Table 1 reports resolution range 30–2.1 Å. — Table 1, AblK:STI571 column; Results, Overall Features of the Structures, p. 4238
ATP-site occupancy and activation-loop conformation: Crystal structure and interaction analysis; PD173955 complex used as comparator. — Figure 3A/B left; Results, Structure of Abl Kinase Domain Bound to STI-571, pp. 4238–4240
ABL inhibition depends on activation-loop phosphorylation
Biochemical assay · Purified murine ABL catalytic domain, compared in phosphorylated and phosphatase-dephosphorylated states [1]
In the same coupled assay, imatinib inhibited dephosphorylated ABL more strongly than phosphorylated ABL; PD173955 inhibited both states.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response experiment; Figure 6A plots STI-571 concentrations in µM. The approximately 100 nM value is an assay IC50, not a fixed treatment concentration.
- Method
- Cell-free peptide phosphorylation assay comparing ABL phosphorylation states.
- Vehicle
- 4% DMSO in the assay.
- Co-treatment
- No therapeutic combination. Phosphatase treatment defines the dephosphorylated enzyme condition; PD173955 tested separately as comparator.
- Reported limits
- Assay duration and replicate/error-bar semantics are not specified in the read kinase-assay methods or Figure 6 caption; no exact IC50 is inferred from the curve.
Methods and source locations
Compound reported in the paper: Imatinib; Compound label in the paper: STI-571
Evidence for the imatinib molecule in the reported system; no validation of Adooq A10259 lots, formulation equivalence or free-base/salt dose conversion.
Figure 6 and caption; Kinase Assays, p. 4238; Results, pp. 4241–4242
Inhibition of dephosphorylated ABL-catalyzed peptide phosphorylation: Continuous NADH-coupled spectrophotometric kinase assay at 340 nm; 0.5 mM ATP, 0.5 mM peptide substrate, 10 nM ABL, 30°C and 4% DMSO. — Figure 6A; Results, p. 4242; Kinase Assays, p. 4238
Inhibition of phosphorylated ABL compared with dephosphorylated ABL: Same kinase assay; phosphorylated versus dephosphorylated ABL, with PD173955 as state-insensitive comparator. — Figure 6A/B and caption; Results, pp. 4241–4242
Acute BCR-ABL pathway inhibition in primary CML stem/progenitor cells
Cell-based study · Primary lineage-negative cells from newly diagnosed chronic-phase CML patients, including CD34+CD38– and CD133+ stem-enriched populations and CD34+CD38+ progenitors; normal marrow controls and BCR-ABL-expressing cell-line comparators [2]
Four-hour imatinib treatment suppressed phosphotyrosine and BCR-ABL substrate phosphorylation in stem-enriched and progenitor populations. Residual signal and an assay-specific phospho-CRKL flow-cytometry limitation prevent equating these readouts with complete abolition of all kinase activity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 µM imatinib in the principal acute comparisons; Figure 1C also compares an imatinib concentration range.
- Exposure duration
- 4 h
- Method
- In vitro exposure under serum/cytokine-free conditions, followed by phosphotyrosine FACS or substrate-phosphorylation immunoblot; corrected immunocytochemical population labels considered.
- Co-treatment
- Imatinib alone; no cytokine cocktail in the selected acute comparisons.
- Reported limits
- Vehicle and reagent salt/supplier/lot are not specified in the read acute assay description. No therapeutic dose or salt conversion inferred.
Methods and source locations
Compound reported in the paper: Imatinib; Compound label in the paper: IM
Evidence for the imatinib molecule in the reported system; no validation of Adooq A10259 lots, formulation equivalence or free-base/salt dose conversion.
Figures 1 and 2A–C; corrected Figure 2D (erratum); Supplemental Figure 1; Results, Imatinib inhibits BCR-ABL in CML stem and progenitor cells; acute assay Methods
Cellular phosphotyrosine in immunophenotypically defined primary CML populations: Intracellular phosphotyrosine FACS; untreated and matched-isotype controls, phenotypically matched normal cells and BCR-ABL-expressing cell lines. Figure 1A: MFI ± SEM, n=10 CML and n=3 normal; Figure 1C: 3 independent CML samples. — Figure 1A–C and caption; Results, first acute target-inhibition subsection
Phospho-CRKL signal in primary CML CD34+ cells: Immunoblot comparison after 4 h imatinib treatment; total CRKL and actin controls. The text reports 75% suppression but also says normal levels were not restored. — Figure 2A and acute target-inhibition Results, paragraph beginning Total phosphotyrosine levels
Agreement of phospho-CRKL readouts in primary CML cells: Within-paper comparison of phospho-CRKL flow cytometry, phospho-CRKL immunoblot and phosphotyrosine flow cytometry. — Supplemental Figure 1A–C and caption; acute target-inhibition Results